Abstract

Ten-Year Response to Crizotinib in ALK-positive Inflammatory Myofibroblastic Tumors: Case Reports

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call